Meeting of the Shareholder No.1/2019 on March 18, 2019 approved the Company and the subsidiary to settle the disputes with EXAT as described in No.1. It is pending to the EXAT proceeding according to the
Total Shareholder Equity 2018 Q1 2019 Unit: THB mm Liabilities As of 31 March 2019, the Company had total liabilities of THB 44,795.5 mm, which decreased by THB 2,535.4 mm from THB 47,330.9 mm as of 31
205mn ordinary shares at an offering price of THB 1.60 per share • On 24 April 2019, the shareholder meeting has approved the cash dividend payment from the operating results of the second half of 2018 at
liabilities have decreased as the Saraburi Acquisition loan and the Hua-Pha-Way Kiln 7 loan continue to be repaid. Shareholder equity increased in-line with the additional net result. Balance Sheet Summary as
Shareholder equity 383.00 383.00 Registered capital Issued and Paid up capital 383.00 16.33% 383.00 16.22% Premium on stock 519.67 22.16% 519.67 22.00% Retained earnings Legal reserve 74.90 3.19% 74.10 3.14% Un
Myco Biotech shares will result in the BS Myco Biotech being a subsidiary of the Company. Shareholder name Before Acquisition After Acquisition 1. Bangjak Green Energy Company Limited 399,990 shares
Million. o Dividend payment of 2018 (April – December) to shareholders whose names appear in the shareholder register as of March 13, 2019 for 280 Million shares at 0.10 Baht per share. Totaling of Baht
Receipt) for the purchase of fuel in H1. Non-current liabilities have decreased as the Saraburi Acquisition loan and the Hua-Pha-Way Kiln 7 loan continue to be repaid. Shareholder equity reduced with the
shareholder at Annual General Meeting resolved to approve the cash dividend payment from the operating results of 2H 2017 at THB 0.018 per share (a total of THB 62mn). The total dividend payment from 2017
in long-term liabilities due to the 330mTHB term loan used to acquire Saraburi Quicklime impacted total liabilities. Shareholder equity increased in-line with the additional net result. Balance Sheet